[1] Zolotas E, Krishnan RG. Nephrotic syndrome[J]. Paediatr Child Health, 2016, 26(8):349-352.
[2] Müller-Deile J, Schiffer M. Podocyte directed therapy of nephrotic syndrome-can we bring the inside out[J]. Pediatr Nephrol, 2016, 31(3):393-405.
[3] Raij L, Tian R, Wong JS, et al. Podocyte injury:the role of proteinuria, urinary plasminogen, and oxidative stress[J]. Am J Physiol Renal Physiol, 2016, 311(6):F1308-F1317.
[4] 郝胜, 吴滢, 何威逊, 等. 儿童原发性肾病综合征肾组织瞬时受体电位阳离子通道蛋白6表达及意义[J]. 临床儿科杂志, 2017, 35(7):498-502.
[5] Ilatovskaya DV, Staruschenko A. TRPC6 channel as an emerging determinant of the podocyte injury susceptibility in kidney diseases[J]. Am J Physiol Renal Physiol, 2015, 309(5):F393-F397.
[6] Dogra S, Kaskel F. Steroid-resistant nephrotic syndrome:a persistent challenge for pediatric nephrology[J]. Pediatr Nephrol, 2017, 32(6):965-974.
[7] 郭晓红, 张涵, 胡杰, 等. 瞬时受体电位阳离子通道蛋白6和整合素连接激酶在以蛋白尿为主要表现的慢性肾脏病中的表达[J]. 中华肾脏病杂志, 2017, 33(5):378-384.
[8] Ilatovskaya DV, Palygin O, Chubinskiy-Nadezhdin V, et al. Angiotensin Ⅱ has acute effects on TRPC6 channels in podocytes of freshly isolated glomeruli[J]. Kidney Int, 2014, 86(3):506-514.
[9] Huang H, You Y, Lin X, et al. Inhibition of TRPC6 signal pathway alleviates podocyte injury induced by TGF-β1[J]. Cell Physiol Biochem, 2017, 41(1):163-172.
[10] Koitabashi N, Aiba T, Hesketh GG, et al. Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation novel mechanism of cardiac stress modulation by PDE5 inhibition[J]. J Mol Cell Cardiol, 2009, 48(4):713-724.
[11] Pollak MR, Quaggin SE, Hoenig MP, et al. The glomerulus:the sphere of influence[J]. Clin J Am Soc Nephrol, 2014, 9(8):1461-1469.
[12] Wieder N, Greka A. Calcium, TRPC channels, and regulation of the actin cytoskeleton in podocytes:towards a future of targeted therapies[J]. Pediatr Nephrol, 2016, 31(7):1047-1054.
[13] Riehle M, Büscher AK, Gohlke BO, et al. TRPC6 G757D loss-of-function mutation associates with FSGS[J]. J Am Soc Nephrol, 2016, 27(9):2771-2783.
[14] Möller CC, Wei C, Altintas MM, et al. Induction of TRPC6 channel in acquired forms of proteinuric kidney disease[J]. J Am Soc Nephrol, 2007, 18(1):29-36.
[15] Winn MP, Conlon PJ, Lynn KL, et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis[J]. Science, 2005, 308(5729):1801-1804
[16] 彭梅,李贵森. TRPC6基因突变致局灶节段性肾小球硬化的研究进展[J]. 实用医院临床杂志, 2016, 13(3):170-173.
[17] Kuang XY, Huang WY, Xu H, et al. 254C>G:a TRPC6 promoter variation associated with enhanced transcription and steroid-resistant nephrotic syndrome in Chinese children[J]. Pediatr Res, 2013, 74:511-516.
[18] Zhang Q, Ma J, Xie J, et al. Screening of ACTN4 and TRPC6 mutations in a Chinese cohort of patients with adult-onset familial focal segmental glomerulosclerosis[J]. Contrib Nephrol, 2013, 181:91-100.
[19] Mahesh Kumar KB, Prabha S, Ramprasad E, et al. TRPC6 gene promoter polymorphisms in steroid resistant nephrotic syndrome children[J]. J Nephropharmacol, 2017, 4(2):52-56
[20] Iqbal Z, Sayer JA. Case Report:Making a diagnosis of familial renal disease -clinical and patient perspectives[J]. F 1000Res, 2017, 6:470.
[21] Reiser J, Polu KR, Möller CC, et al. TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function[J]. Nat Genet, 2005, 37(7):739-744.
[22] Hofstra JM, Coenen MJ, Schijvenaars MM, et al. TRPC6 single nucleotide polymorphisms and progression of idiopathic membranous nephropathy[J]. PLoS One, 2014, 9(7):e102065.
[23] Chen WC, Chen SY, Chen CH. et al. Lack of association between transient receptor potential cation channel 6 polymorphisms and primary membranous glomerulonephritis[J]. Ren Fail, 2010, 32(6):666-672.
[24] Kistler AD, Singh G, Altintas MM, et al. Transient receptor potential channel 6(TRPC6) protects podocytes during complement-mediated glomerular disease[J]. J Biol Chem, 2013, 288(51):36598-36609.
[25] Yu S, Yu L. Dexamethasone resisted podocyte injury via stabilizing TRPC6 expression and distribution[J]. Evid Based Complement Alternat Med, 2012, 2012:652059.
[26] Sun X, Fang Z, Zhu Z, et al. Effect of down-regulation of TRPC6 on the puromycin aminonucleoside-induced apoptosis of mouse podocytes[J]. J Huazhong Univ Sci Technolog(Med Sci), 2009, 29(4):417-422.
[27] Sonneveld R, van der Vlag J, Baltissen MP, et al. Glucose specifically regulates TRPC6 expression in the podocyte in an AngⅡ-dependent manner[J]. Am J Pathol, 2014, 184(6):1715-1726.
[28] 胡春丽, 谢席胜, 冯胜刚. 高糖对小鼠足细胞TRPC6表达的影响[J]. 西部医学, 2017, 29(1):22-26.
[29] 胡春丽, 谢席胜, 冯胜刚. 厄贝沙坦对高糖诱导的小鼠足细胞瞬时受体电位阳离子通道蛋白6表达的影响[J]. 临床肾脏病杂志, 2016, 16(12):744-749.
[30] 任直亲,范慧,李芳芳, 等.缬沙坦对糖尿病肾病大鼠肾脏TRPC6表达的影响[J].糖尿病新世界, 2016, 19(11):48-49.
[31] Yao XM, Liu YJ, Wang YM, et al. Astragaloside IV prevents high glucose-induced podocyte apoptosis via downregulation of TRPC6[J]. Mol Med Report, 2016, 13(6):5149-5156.
[32] Ma R, Liu L, Jiang W, et al. FK506 ameliorates podocyte injury in type 2 diabetic nephropathy by down-regulating TRPC6 and NFAT expression[J]. Int J Clin Exp Pathol, 2016, 8(11):14063-14074.
[33] Ilatovskaya DV, Levchenko V, Lowing A. et al. Podocyte injury in diabetic nephropathy:implications of angiotensin Ⅱ-dependent activation of TRPC channels[J]. Sci Rep, 2015, 5:17637.
[34] do Nascimento JF, Canani LH, Gerchman F, et al. Messenger RNA levels of podocyte-associated proteins in subjects with different degrees of glucose tolerance with or without nephropathy[J]. BMC Nephrol, 2013, 14:214.
[35] Wu YL, Xie J, An SW, et al. Inhibition of TRPC6 channels ameliorates renal fibrosis and contributes to renal protection by soluble klotho[J]. Kidney Int, 2017, 91(4):830-841.
[36] 张磊, 陈秀萍, 蒋玲, 等. 全反式维甲酸对肾小球硬化大鼠肾小球TRPC6表达的影响[J]. 实用医学杂志, 2016, 32(23):3827-3831.
[37] 黄海庭, 吴好好, 覃幼玲, 等. 黄芪总苷对TGF-β1诱导下足细胞TRPC6表达的影响[J]. 中国免疫学杂志, 2017, 33(3):370-373.
[38] Hagmann H, Mangold N, Rinschen MM, et al. Proline-dependent and basophilic kinases phosphorylate human TRPC6 at serine 14 to control channel activity through increased membrane expression[J]. FASEB J, 2017 Sep 6. pii:fj.201700309R.
[39] Urban N, Wang L, Kwiek S, et al. Identification and validation of larixyl acetate as a potent TRPC6 inhibitor[J]. Mol Pharmacol, 2016, 89(1):197-213.
[40] Kim EY, Roshanravan H, Dryer SE, et al. Changes in podocyte TRPC channels evoked by plasma and sera from patients with recurrent FSGS and by putative glomerular permeability factors[J]. Biochim Biophys Acta, 2017, 1863(9):2342-2354.